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Abstract (250 words) (Background, aims, results, conclusions) 
Zinc 2 glycoprotein (ZAG) is an adipokine with a class I major histocompatibility complex protein 
fold and is associated with obesity and diabetes. Although its intrinsic ligand remains unknown, ZAG 
binds the dansylated C11 fatty acid, DAUDA, in the groove between the 1 and 2 domains. The 
surface of ZAG has about 15 weak zinc binding sites deemed responsible for precipitation from 
human plasma. Here the functional significance of these metal sites was investigated. Analytical 
ultracentrifugation and circular dichroism showed that zinc, but not other divalent metals, cause 
ZAG to oligomerise in solution. Thus ZAG dimers and trimers were observed in the presence of 1 mM 
and 2 mM zinc. Molecular modelling of X-ray scattering curves and sedimentation coefficients 
indicated a progressive stacking of ZAG monomers, suggesting the ZAG groove may be occluded in 
these. Using fluorescence-detected sedimentation velocity, these ZAG-zinc oligomers were again 
observed in the presence of the fluorescent boron dipyrromethene fatty acid C16-BODIPY. 
Fluorescence spectroscopy confirmed that ZAG binds C16-BODIPY.  ZAG binding to C16-BODIPY, but 
not to DAUDA, was reduced by increased zinc concentrations. We conclude that the lipid binding 
groove in ZAG contains at least two distinct fatty acid binding sites for DAUDA and C16-BODIPY, 
similar to the multiple lipid binding seen in the structurally-related immune protein Cd1c. In 
addition, because high concentrations of zinc occur in the pancreas, the perturbation of these 
multiple lipid binding sites by zinc may be significant in Type 2 diabetes where dysregulation of ZAG 
and zinc homeostasis occurs. (247 words) 
Summary statement (40 words): Zinc causes the adipokine and class I MHC-like protein, zinc 2 
glycoprotein (ZAG), to oligomerize in solution. Our experiments reveal the presence of two distinct 
fatty acid binding sites within ZAG, of which one is abrogated by oligomer formation. (39 words) 
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INTRODUCTION  
In 2014, the global presence of diabetes was estimated to be 9% among adults [1]. Diabetes is 
associated with obesity and increases the risk of heart disease, stroke, blindness and kidney failure. 
If untreated, the World Health Organisation predicts that diabetes will be the seventh leading cause 
of death in 2030 [1]. The plasma protein zinc-α2-glycoprotein (ZAG) has been associated with type 2 
diabetes. ZAG was first isolated from human plasma in 1961 by precipitation with zinc salts [2]. ZAG 
is expressed in the pancreas [3] and secreted from adipocytes, defining it as an adipokine [4]. The 
expression of ZAG in adipocytes is inversely associated with body fat mass [5, 6]. Indeed 
subcutaneous white fat from type 2 diabetic patients shows reduced expression of ZAG compared 
with healthy control patients [7, 8]. ZAG is upregulated in urine from diabetic patients [9, 10] and 
contains a non-synonymous single nucleotide polymorphism rs4215 associated with obesity [11, 12]. 
ZAG also participates in lipolysis and the control of body fat mass [5, 13]; treatment of ob / ob mice 
with ZAG resulted in an increase in pancreatic insulin and a reduction in plasma glucose [14]. 
Meanwhile incubation of human primary skeletal muscle with ZAG caused an increase in the 
expression of glucose transporter type 4 and activation of AMPK, a regulator of energy metabolism 
[15]. Despite these cellular observations, the molecular function of ZAG has remained elusive. 
Determining the molecular mechanism of ZAG is important not only in understanding how body fat 
mass is controlled, but also in uncovering the biochemical basis of its contribution to the pathology 
of type 2 diabetes. 
The protein structure of ZAG exhibits a class I major histocompatibility complex (MHC) protein fold 
with two αhelices that define a groove [16]. However, ZAG is distinct from other MHC immune 
proteins in three aspects: (i) ZAG is soluble, rather than being anchored to plasma membranes; (ii) 
ZAG associates with prolactin-inducible protein rather than 2-microglobulin [17], and (iii) ZAG binds 
small hydrophobic ligands rather than antigenic peptides in its αhelical groove [18]. Unlike the 
classic MHC proteins, the binding groove in ZAG contains one charged residue Arg73, but is 
otherwise lined by hydrophobic residues [16]. In keeping with this observation, site-directed 
mutagenesis and fluorescence measurements revealed that ZAG binds polyunsaturated fatty acids 
with µM affinity in its groove [19]. The actual ligand occupying the ZAG groove in vivo has yet to be 
discovered and will be crucial to understanding the molecular mechanism of ZAG. To initiate this 
analysis, we have shown that ZAG contains one tightly-bound zinc ion, predicted to bind close to its 
groove, plus approximately 15 weak zinc binding sites on the protein surface [20]. The weak zinc 
binding sites are deemed responsible for the precipitation of ZAG from plasma [2].  
Here, we analyse the relationship of zinc binding to ZAG with its presumed lipid-binding function 
using a combination of biophysical approaches. Using analytical ultracentrifugation (AUC), small 
angle X-ray scattering (SAXS) and circular dichroism (CD) to monitor the oligomerisation and 
conformation of ZAG, we show that the weak zinc binding sites are specific only for zinc, and not for 
other bivalent metals, and zinc causes ZAG to self-associate to form oligomers. The use of SAXS and 
AUC molecular modelling showed that the oligomers form via a stacking mechanism which occludes 
the ZAG groove. The use of a fluorescent-labelled fatty acid permitted a recently-developed method 
termed fluorescent-detected AUC (AUC-FDS) to follow the binding of a fluorescent-labelled fatty acid 
C16-BODIPY to ZAG, which further revealed that zinc also promotes oligomerisation of the C16-
BODIPY:ZAG complex. Fluorescence spectroscopy demonstrated that ZAG binds the fluorescent fatty 
acid C16-BODIPY in a hydrophobic environment but that the binding of C16-BODIPY to ZAG was 
abrogated with increasing zinc concentrations. In contrast the binding of the fluorescent dansylated 
C10-fatty acid, DAUDA, to ZAG was not affected by additions of zinc. We show for the first time that 
the ZAG groove contains multiple fatty acid binding sites, and discuss the functional significance of 
this outcome.  
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EXPERIMENTAL   
Purification of ZAG in the presence of divalent metals 
Starting from a pET23a clone containing human ZAG, ZAG was purified from inclusion bodies using 6 
M guanidine hydrochloride [20]. Denatured ZAG was gradually added to 1 L refolding buffer at 4°C. 
Vivaspin centrifugal concentrators (MWCO 10 kDa; Sartorius) were used to concentrate the refolded 
ZAG solution to 5 ml. ZAG was dialyzed overnight against 1 L of 10 mM Hepes, 137 mM NaCl, pH 7.4 
(Hepes buffer) at 4°C with three buffer changes. ZAG was further purified using a GE Superdex 200 
size-exclusion chromatography column equilibrated with Hepes buffer at a flow rate of 2 ml/min. 
Fractions corresponding to the ZAG elution peak were collected and its purity was confirmed by the 
observation of a single band on 15% SDS PAGE corresponding to the 32 kDa ZAG protein [20]. The 
concentration of ZAG was determined using a spectrophotometer (Perkin Elmer Lambda 35) with a 
theoretical molecular mass of 32,278 Da and extinction coefficient of 71,071 M-1cm-1 calculated from 
the amino acid content [21]. The protein was used immediately in experiments. Analytical size-
exclusion chromatography was performed using a Superdex 75 gel filtration column equilibrated 
with Hepes buffer on its own or with 2 mM of a metal chloride, pH 7.4, at a flow rate of 0.5 ml/min. 
100 µL of 6.2 µM ZAG was injected onto the column in the absence and presence of 2 mM metal 
chlorides. Individual samples were run in duplicate. Native PAGE was performed using 4-20% Mini-
PROTEAN Precast Gels (Bio-Rad).  
 
Dynamic light scattering (DLS) 
Dynamic light scattering, experiments were made with a Zetasizer Nano range instrument (Malvern). 
Sterile filtered ZAG (21 μM) in Hepes buffer was titrated with increasing concentrations of zinc and 
barium chlorides, followed by the addition of excess EDTA. Samples were measured in triplicate 
using 10 mm path length cuvettes at 25°C and assuming a buffer viscosity of 1.0300 cp.  
 
Circular dichroism (CD) 
An Applied Photophysics Chirascan Plus™ spectrometer (Leatherhead, UK) was used to measure the 
UV absorbance and the ‘near and far-UV’ CD spectra of ZAG titrated with increasing concentrations 
of metal chlorides (barium, calcium, manganese, cobalt, nickel and zinc). The UV absorbance and 
‘near-UV’ CD spectra of ZAG were measured using a 10 mm path length cuvette in a wavelength 
range between 230-400 nm. The ‘far-UV’ CD spectra of ZAG were measured using a 0.5 mm path 
length cuvette in a wavelength range between 190-260 nm. The CD instrument was flushed 
continuously with nitrogen gas and all spectra were recorded using a 1 nm spectral bandwidth, 1 nm 
step size and a 1.5 s instrument time-per-point. All measurements were made at 23°C using 6.2 µM 
ZAG and metal ion solutions in 10 mM Hepes, pH 7.4. A buffer baseline was subtracted from each 
sample spectrum prior to correction for the effects of dilution.  
 
Analytical ultracentrifugation (AUC) and fluorescence detected AUC (AUC-FDS) 
AUC experiments were performed using two XL-I Beckman-Coulter instruments equipped with 
An50Ti rotors, using velocity cells with two-sector aluminium centrepieces at rotor speeds of 50,000 
rpm at 20°C. Sedimentation velocity experiments were performed with 6.2 µM ZAG in Hepes buffer 
which was titrated with zinc or barium chloride at concentrations of 0 mM, 0.5 mM, 1.0 mM and 2 
mM metal, and with 7.5 mM EDTA. The buffer density for each sample was determined using an 
Anton Paar DMA 5000 density meter. SEDFIT software (version 14.6) was used to analyse the 
absorbance data recorded at 280 nm. The Lamm equation was directly fitted to every third boundary 
scan of a total of 150 scans in order to obtain the size distribution analysis c(s) that provided the s20,w 
and mass values. The c(s) analyses were based on a fixed resolution of 200, minimum and maximum 
sedimentation coefficients (Smin and Smax) of 0.5 S and 15 S respectively, a frictional ratio of 1.2, a 
meniscus of 6.2 cm, the bottom of the cell set at 7.2 cm, a confidence level (F-ratio) of 0.95, a partial 
specific volume of 0.730 ml/g, and buffer viscosity of 1.02369 cp (theoretical value calculated using 
SEDNTERP software [22]). The baseline, meniscus and bottom of the cell were floated for the fits. 
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Using the integration function in the c(s) analysis, the amounts of ZAG monomer and oligomers were 
quantitated. A fluorescence detector retrofit system (AVIV Biomedical) on one AUC instrument 
allowed AUC-FDS measurements of the sedimentation of 6.2 µM C16-BODIPY (4, 4-difluoro-5, 7-
dimethyl-4-bora-3a, 4a-diaza-s-indacene-3-hexadecanoic acid; λExc = 488 nm) in the presence of 6.2 
µM ZAG and 0.5 mM, 1.0 mM or 2.0 mM zinc chloride to be made. A five-channel charcoal epon 
calibration centre piece was used where channel A contained 100 nM fluorescein isothiocyanate 
(Sigma Aldrich). Data were analysed using SEDFIT software as described above.  
 
Small angle X-ray scattering  
SAXS measurements on ZAG were carried out at the European Synchrotron Radiation Facility 
(Grenoble, France) on the BioSAXS BM29 beam line in 7/8 multibunch beam mode [23, 24]. The X-
ray wavelength was 0.0992 nm and the sample-detector distance was 2.87 m. The absence of 
radiation damage to the sample was confirmed through on-line checks at low Q values, and 
potential damage eliminated through the continuous movement of the flow cell during beam 
exposure. ZAG was loaded at a concentration of 0.5 mg/ml (15.5 M) in Hepes buffer. Zinc and 
barium chloride concentrations were added to the protein in Hepes buffer 24 h before loading onto 
the beam line. Data was acquired in time frames of 1 s for 10 frames per run. For analyses, the final 
curves were averaged following the subtraction of 10 raw buffer files from 10 samples files. In a 
given solute–solvent contrast, the radius of gyration RG is a measure of structural elongation if the 
internal inhomogeneity of scattering densities within the protein has no effect, being defined as the 
root mean square of distances within the protein relative to its centre of scattering density. Guinier 
analyses at low Q (where Q = 4π sin θ/λ; 2θ is the scattering angle and λ is the wavelength) gives the 
RG and the forward scattering at zero angle I(0) [25]: 
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The Guinier analyses were performed in a Q range of 0.20-0.42 nm-1 using SCT software [26]. The 
distance distribution function P(r) was generated using GNOM software [27] and gives alternative 
determinations of the RG and I(0) values.  
 
The theoretical X-ray scattering curve was calculated from the ZAG crystal structure (PDB code 1T7Z) 
[18], following its conversion from atomic coordinates to a coarse-grained model and the addition of 
hydration spheres using SCT software [26]. Putative ZAG oligomers were generated using PyMOL 
software and the ZAG crystal structure for similar calculations [18].  For ultracentrifugation 
modelling, the atomic coordinate files for the ZAG monomer and oligomers were inputted into the 
HydroPRO shell modelling software to generate theoretical sedimentation coefficient s020,w values 
[28].   
 
Fluorescence spectroscopy 
Fluorescence measurements were recorded at 22°C with a Perkin Elmer LS50B Luminscence 
Spectrometer (Bucks, UK) using 2 ml samples in a quartz cuvette, path length = 1 cm. The three 
fluorescent fatty acid probes C11-BODIPY (4,4-difluoro-5,7-dimethyl-4-bora-3a-4a-diaza-s-Indacene-
3-undecanoic acid), C16-BODIPY and DAUDA (11-((5-dimethylaminonapthalene-1-sulphonyl)amino) 
undecanoic acid) were obtained from Thermo Fisher Scientific Life Technologies. C11- and C16-BODIPY 
were both stored as stock solutions of ~3 mg/ml in DMSO. DAUDA was stored as a stock solution of 
~1.5 mg/ml in ethanol. All fluorescent fatty acids were stored in the dark at -20 ˚C and freshly diluted 
before experiments into methanol, phosphate buffered saline (PBS; 137 mM NaCl, 20 mM Na2HPO4, 
2.7 mM KCl and 1.5 mM KH2PO4) or Hepes buffer.  The accurate concentrations of C11- and C16-
BODIPY and DAUDA were calculated using 550 = 86,000 M
-1 cm-1, 550 = 93,000 M
-1 cm-1 and 340 = 
4,400 M-1 cm-1 in methanol respectively, all values obtained from the manufacturers’ data sheets. 
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The fluorescence emission intensities of C11-BODIPY and C16-BODIPY were examined in methanol and 
PBS and upon addition of ZAG, (ex = 488 nm). 0.89 M DAUDA (ex = 345 nm) and 0.85 M C16-
BODIPY (ex = 488nm) were individually titrated with sequential additions of ZAG. The titrations were 
repeated in buffer containing 0.5 mM, 1 mM, 1.5 mM and 2 mM ZnCl2. The titration curves were 
fitted using standard nonlinear regression techniques to a single noncompetitive binding model to 
generate dissociation constant Kd values [20]. Control experiments of 0.89 M DAUDA and 0.85 M 
C16-BODIPY fluorescence emission in buffer containing 0, 0.5, 1.0, 1.5 and 2 mM ZnCl2 revealed that 
the fluorescence emission of both probes were quenched upon addition of zinc. The quenching 
effect was accordingly corrected for this by subtraction of the DAUDA / C16-BODIPY spectrum from 
the fluorescence emission profiles generated upon additions of ZAG. Fluorescence spectra were also 
corrected for the effects of dilution and, where noted, solvent Raman scattering was corrected by 
subtracting the buffer-only spectrum.  
 
RESULTS  
 
Metal-induced association of ZAG  
In order to investigate why ZAG was precipitated by zinc and not by other metals, the metal binding 
specificity of ZAG was first examined by SEC, native PAGE and DLS. A much-decreased intensity of 
absorbance at 280 nm and a significant change in the ZAG elution time range (from 23 to 25 min) 
were observed upon addition of zinc, but not for the other five divalent metals tested (Figure 1A). 
Upon addition of zinc, the ZAG elution peak did not return to baseline, implying that ZAG-zinc had 
aggregated in the column and was gradually released upon further elution. In agreement with our 
previous study that revealed weak zinc binding to the surface of ZAG [20], these changes were 
reversible upon addition of EDTA. ZAG migrated as a single band on non-reducing native PAGE in the 
presence of seven divalent metals and in EDTA (Figure 1B). DLS revealed monomer ZAG to have a 
mean hydrodynamic radius Rh of 3.22 nm (Figure 1C, 1D; Table 1). Addition of increasing 
concentrations of zinc chloride to the ZAG solution caused the Rh value of ZAG to increase. In the 
presence of 2 mM zinc chloride, two peaks were observed corresponding to mean Rh values of 8.38 
nm and 33.17 nm. These changes were reversed upon addition of excess EDTA where the mean Rh 
value of ZAG reverted back to 4 nm. Control experiments with the buffer alone in the absence of 
ZAG confirmed these results were due to ZAG-zinc complex formation. In contrast, titrating ZAG with 
increasing concentrations of barium chloride did not increase the mean Rh value of ZAG above 4.63 
nm (Figure 1C, 1D; Table 1). It was inferred that zinc-ZAG aggregates were detected by DLS that were 
too weakly associated to be resolved using size-exclusion chromatography and native PAGE. In 
agreement with this, we had previously measured a Kd of 100 µM for the strongest of the weak zinc 
binding sites in ZAG [20]. 
 
To probe further the metal binding specificity of ZAG, UV spectroscopy measurements were made to 
follow turbidity changes in ZAG. In agreement with our DLS observations, addition of 1.8 mM zinc 
chloride to ZAG, but not the other divalent metal ions, significantly increased the apparent 
absorbance over the entire wavelength range of 240-400 nm (Figure 2A). The apparent absorbance 
increase was attributed to underlying turbidity contributions.  The existence of turbidity (light 
scattering), totally responsible for the apparent absorbance above 310 nm, indicated that ZAG forms 
aggregates in the presence of Zn2+ ions. Co2+ and Ni2+ ions also caused slight increases in absorbance 
(turbidity) upon addition to ZAG, but these were negligible compared with Zn2+. Through monitoring 
turbidity changes at 340 nm, the titrations of ZAG with five divalent metal chlorides confirmed a 
zinc-specific effect with the zinc-induced precipitation or aggregation displaying a sigmoidal curve 
(Figure 2B). Even though calcium and barium can form divalent complexes with negatively charged 
residues on proteins, here neither Ca2+ nor Ba2+ produced turbidity. Ca2+ and Ba2+ ions are larger and 
less charge-dense than Zn2+ ions and obviously not conducive to the formation of ZAG oligomers. 
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These metal-specific changes were further confirmed using CD to follow conformational changes in 
ZAG. The ‘near-UV’ CD spectrum of ZAG was significantly altered upon addition of zinc chloride, 
while only minor alterations in the spectrum were observed upon addition of cobalt or nickel 
chloride (Figure 2C). This result suggests that metal-induced changes occurred in the tertiary 
structure of ZAG that followed the order zinc > nickel  cobalt. Our observations were in line with 
the Irving-Williams series of transition metals which stated that the stability of metal : protein 
complexes follows the order Mn < Fe < Co < Ni < Cu > Zn [29]. The ‘far-UV’ CD spectrum of ZAG 
showed no significant changes in the broad negative peak at 218 nm upon addition of 1.8 mM of 
barium, calcium, manganese, cobalt and nickel chlorides, also suggesting no significant changes in 
the secondary structure of ZAG (Figure 2D). Addition of 1.8 mM zinc chloride decreased the intensity 
of the broad negative peak observed at 218 nm, showing a significant change in the ‘far-UV’ CD 
spectrum compared with that of ZAG alone, suggesting zinc-induced conformational changes had 
occurred in the secondary structure of ZAG.  
 
Oligomeric structure of zinc-induced aggregates of ZAG 
To identify the nature of the zinc-specific ZAG aggregates, AUC measurements were performed with 
ZAG in the presence of zinc chloride, with barium chloride used as a control. Samples were subjected 
to a high centrifugal force, and an absorbance optical system was used to observe the sedimentation 
of ZAG in real time. The sedimentation boundaries (Figures 3A-C) were well fitted to size distribution 
analyses (Experimental). In comparison with ZAG alone, more rapid sedimentation boundaries were 
observed upon addition of 2 mM ZnCl2 (Figures 3A, 3B). In contrast, the addition of 2 mM BaCl2, 
caused no significant changes in sedimentation compared to ZAG alone (Figure 3C). Size distribution 
c(s) analyses for the five zinc and barium concentrations revealed the presence of a ZAG monomer 
peak at a mean s20,w value of 2.83 ± 0.02 S (Figure 3D and 3E). Mass distribution c(M) plots showed 
that this ZAG monomer peak corresponded to a mean molecular mass of 32 ± 0.5 kDa, which agreed 
well with the sequence-determined mass of 32 kDa. The intensities of the ZAG monomer peak were 
significantly reduced with additions of zinc, but not with barium. The c(s) analyses further showed 
that increasing the concentrations of zinc chloride to 1 mM and 2 mM gave rise to two additional 
peaks at S values of 4.07 S and 5.2 S that correspond to molecular masses of 68 kDa and 103 kDa, 
respectively (Figure 3D). These peaks correspond well to ZAG dimer and trimer formation. The broad 
nature of these dimer and trimer peaks indicated that these peaks may also correspond to low 
proportions of other ZAG oligomers of increased sizes in equilibrium with the monomer, dimer and 
trimer peaks. In contrast to zinc, an almost insignificant oligomer peak was visible for barium. The 
integrations of Figure 3F showed that the oligomers increased with decrease in ZAG monomer in the 
case of zinc, but not with barium. These protein-zinc oligomers have been seen previously; the 
human complement regulator factor H, complement protein C3 [30], and adiponectin also form 
oligomers in the presence of zinc [31], while zinc induces dimerization of the class II MHC molecule 
HLA-DR1 in a complex with a hemagglutinin peptide [32]. 
 
To determine whether similar ZAG-zinc oligomers were formed in the presence of fatty acids, AUC-
FDS measurements were performed to track the movement of the fluorescent fatty acid C16-BODIPY. 
In the presence of 0.5 mM ZnCl2 and ZAG, a fluorescent sedimentation boundary was observed for 
C16 BODIPY (Figure 4A). This corresponded to a ZAG monomer peak of mean s20,w value 2.72 S in the 
c(S) analysis, indicating that C16-BODIPY was bound to sedimenting ZAG in the presence of 0.5 mM 
ZnCl2 (Figure 4E). No fluorescent sedimentation was observed for C16-BODIPY on its own. The 
addition of 2 mM ZnCl2 revealed more rapidly moving fluorescent sedimentation boundaries (Figure 
4C). Indeed the c(s) analyses showed that increasing the concentrations of zinc chloride to 1 mM and 
2 mM gave rise to ZAG-C16-BODIPY s20,w values of 4.14 S and 4.93 S that corresponded to molecular 
masses of 53 kDa and 70.2 kDa, respectively (Figure 4D). These two fluorescent peaks corresponded 
approximately to ZAG-C16-BODIPY dimer and trimer formation. Following completion of this AUC-FDS 
experiment, the samples were re-suspended for conventional absorbance AUC that followed only 
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the sedimentating protein. This control revealed similar results with regards to the sedimentation 
boundaries (Figures 4B and 4D) to those in Figure 3B. The absorbance c(s) analyses showed a 
monomer peak and a partly-formed dimer peak upon addition of 2 mM ZnCl2 (Figure 4F), although 
no trimer peak was now observable, attributable to the different type of experiment in use.  
 
To observe further the overall structure of ZAG, SAXS measurements were performed with ZAG in 
the presence and absence of Zn2+ and Ba2+.  SAXS data collection is sensitive to aggregate formation. 
For the ZAG-zinc interaction in one session, experiments were performed at a pH of 6.9 in the same 
Hepes buffer, and these showed that the RG values of ZAG increased from 2.48 nm to 2.71 nm in 
linear Guinier plots on going from 0 mM zinc to 2 mM zinc (data not shown). This RG increase 
indicated oligomer formation, however SAXS was not able to resolve more detail than this. These RG 
increases did not occur in the presence of increasing barium chloride concentrations. For the ZAG-
barium titration series in a second session, the Guinier fits also gave high quality linear fits with RG 
values of between 2.41 ± 0.01 nm and 2.48 ± 0.01 nm in satisfactory Q.RG ranges (Figure 5A). These 
were in good agreement with the RG value of 2.58 ± 0.01 nm for ZAG alone. The distance distribution 
function P(r) was calculated from the full scattering curve I(Q) to produce a histogram of the 
distances between all the pairs of atoms within ZAG. From the P(r) curve, the RG value was 
determined to be 2.32 ± 0.27 nm with a maximum dimension L of 8 nm (Figure 5B). Again, neither 
the RG nor the L values changed significantly upon addition of increasing BaCl2 concentrations. 
Inspection of the unhydrated ZAG crystal structure showed that its maximum dimension is 7.4 nm, 
which is 0.5 nm less than the L value of ZAG from the P(r) curves. This difference is attributable to 
the thickness of the water hydration shell surrounding the ZAG protein surface [33]. In order to 
confirm that the ZAG crystal structure corresponds to its structure in solution, the excellent 
scattering curve fit of the experimental data with the theoretical curve calculated from the hydrated 
ZAG crystal structure showed that ZAG is well represented in solution by its atomistic crystal 
structure (Figure 5C). 
 
Fatty acid binding to ZAG in the absence and presence of zinc 
The dansylated C11 fatty acid probe, DAUDA, has previously been shown to bind between the α1 and 
α2 domain helices of ZAG by site-directed mutagenesis studies [19]. For AUC-FDS studies, the 
DAUDA excitation and emission parameters do not match those of the fluorescence detector, so 
could not be used. Instead, the boron dipyrromethene fatty acid probe C16-BODIPY was used, given 
that its excitation and emission parameters match the AUC-FDS detector. To confirm that C16-
BODIPY bound as expected to ZAG, the fluorescence profiles of C11-BODIPY and C16-BODIPY were 
recorded to reveal low fluorescent emissions at a wavelength maximum of 511 nm in PBS (Figure 6A 
and 6B). In methanol, these fluorescence emission intensities were dramatically increased (Figure 6A 
and 6B). Addition of ZAG to C16-BODIPY in PBS produced a large increase in fluorescence emission 
intensity and a red shift in the wavelength maximum of emission (from 512 nm to 518 nm; Figure 
6C) suggesting that C16-BODIPY has bound to ZAG in a more hydrophobic environment, which was 
presumed to be the ZAG groove. A similar shift (from 514 nm to 518 nm) and increase in intensity 
were reported for the binding of intracellular liver and intestinal type fatty acid binding proteins to 
C16-BODIPY [34]. On the contrary, the fluorescence emission intensity of C11-BODIPY did not change 
significantly upon the addition of ZAG (Figure 6D), indicating that C11-BODIPY did not bind to ZAG. 
Importantly this experiment revealed that the boron dipyrromethene moiety of BODIPY did not 
associate with ZAG, and that the C16 fatty acid was preferred over C11-BODIPY in binding to ZAG. 
Interestingly, ZAG binds DAUDA but not C11-BODIPY, both of which contain undecanoic acid as the 
fatty acid chain. The DAUDA binding site in ZAG is not attributable to the dansyl fluorophore given 
that this alone does not bind to ZAG  [35].  Because no long chain derivatives of DAUDA currently 
exist, we were unable to compare long and short chain fatty acid binding using dansylated fatty 
acids. We presume that the larger size of the BODIPY moiety compared to the dansyl moiety, 
prevents the binding of its undecanoic fatty acid to its site in ZAG.  
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To determine whether the zinc-ZAG oligomers showed altered functional properties in binding to 
fatty acids, ZAG titrations were performed using C16-BODIPY and DAUDA in the absence and 
presence of Zn2+. Incremental additions of ZAG protein to C16-BODIPY caused increased intensities 
and a red shift in the C16-BODIPY fluorescence emission, and these reached saturation upon the 
addition of approximately 2 µM ZAG (Figure 7A). A standard hyperbolic/non-cooperative binding 
model based on a 1:1 stoichiometry gave a ZAG: C16-BODIPY dissociation constant Kd of 0.06 ± 0.01 
µM (Table 2; Figure 7A). The C16-BODIPY fluorescence emission was quenched upon addition of Zn
2+ 
(Figure 7B). Quenching was presumed to occur via photo-induced electron transfer though the 
association of zinc with the deprotonated carboxylic acid of C16-BODIPY (pKa ~ 5) and the lone pair of 
the nitrogen atom disrupting the molecular C=C framework within the BODIPY moiety. The presence 
of increasing Zn2+ concentrations reduced the ability of ZAG to bind C16-BODIPY; the Kd values 
increased to between 8.7 – 22.8 µM indicative of weaker binding of C16-BODIPY to ZAG-zinc (Table 2, 
Figure 7C). In marked contrast to C16-BODIPY, DAUDA binding to ZAG was not significantly affected 
by the presence of increasing Zn2+ concentrations. Upon addition of ZAG, the DAUDA emission 
underwent a blue shift from 543 nm to 519 nm with an increase in emission intensity that reached 
saturation upon addition of approximately 0.2 µM ZAG (Figure 7D). Fitting of this data to a standard 
hyperbolic/non-cooperative binding model based on a 1:1 stoichiometry gave a ZAG: DAUDA Kd 
value of 0.11 ± 0.01 µM (Table 2). We previously reported quenching of DAUDA fluorescence upon 
addition of Zn2+ [20] although the effect is markedly smaller in comparison to the quenching of C16-
BODIPY by Zn2+ (Figure 7E).When the ZAG-DAUDA titration was repeated in the presence of 0.5 mM, 
1 mM and 1.5 mM ZnCl2 (Figure 7F), similar titration curves were observed with unchanged Kd values 
of 0.05 – 0.07 µM (Table 2). In 2 mM ZnCl2, a larger increase in the fluorescence emission intensity 
was observed together with a Kd value of 0.17 µM
-1. Overall, it was concluded that, unlike C16-
BODIPY, DAUDA is able to bind to ZAG-zinc oligomers.  
 
Modelling of ZAG-zinc oligomer formation 
To clarify a molecular mechanism for the zinc-induced oligomerisation of ZAG, structures for the ZAG 
oligomers were modelled, starting from the knowledge that the X-ray scattering curve of ZAG fitted 
its crystal structure (Figure 5C). By trial and error, an arrangement of ZAG oligomers that generated 
close agreement between the experimental and theoretical s20,w values was found to involve the 
compact stacking of ZAG monomers on top of each other in the same orientation (Figure 8A). The 
experimental s20,w values were 2.70 S, 4.07 S and 5.20 S for the monomer, dimer and trimer; the 
modelled values were 2.57 S, 4.08 S and 5.30 S respectively. This good agreement is well within the 
error of ±0.21 S for these comparisons [36]. Previously, we showed that the surface of ZAG contains 
approximately 15 weak zinc binding sites [20]. The surface of ZAG is rich in negatively-charged acidic 
Asp and Glu residues (Figure 8B). Zn2+ adopts tetrahedral co-ordination with proteins, typically 
involving Asp, Glu, His and Cys residues [37], of which there are 18 Asp, 21 Glu, 7 His and 4 Cys 
residues in ZAG. While the four Cys residues are involved in intramolecular disulphide bridge 
formation, all the Asp and Glu residues are located on the ZAG surface. Presumably the stacking of 
ZAG into dimers and trimers is stabilised by the formation of weak zinc binding sites at an extensive 
interface formed between compactly-associated ZAG monomers in which zinc crosslinks these 
surface Asp and Glu residues. Because oligomer formation can be extended indefinitely in such an 
arrangement, this stacking model provides an explanation for why ZAG is precipitated by Zn2+ at high 
Zn2+ concentrations.  
 
DISCUSSION 
Our investigations revealed new insights into the ZAG-zinc and ZAG-fatty acid complexes and 
their functional significance. Thus we have developed a molecular model for the stacking of ZAG-zinc 
oligomers from the modelling of the SAXS and AUC data, and this is able to explain how ZAG is 
precipitated by excess zinc. Such a model suggests that, as the Zn2+ concentration increases, the ZAG 
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lipid-binding groove will be shielded and inhibit the ability of ZAG to bind fatty acids. This deduction 
accounts for our observation of reduced C16-BODIPY binding to ZAG in the presence of increasing 
Zn2+ concentrations (Figure 7A). Notably the same effects were not observed for DAUDA (Figure 7B). 
This difference can be explained by the existence of at least two distinct lipid binding sites in the ZAG 
groove, one for each of DAUDA (unaffected by ZAG-zinc stacking) and C16-BODIPY (inhibited by ZAG-
zinc stacking). More support for the concept of two different binding sites is provided as follows: 
(i) The interaction of DAUDA with ZAG is well characterized. Arachidonic and 
docosahexaenoic acids are able to displace DAUDA from the ZAG groove [35, 18]. The ZAG groove 
contains five tryptophan residues whose fluorescence is quenched and blue shifted upon addition of 
arachidonic and docosahexaenoic acids. However no binding data for these fatty acids had been 
reported in these studies, and we have not investigated this here. In addition, site-directed 
mutagenesis has shown that mutation of the hydrophobic groove residues Y14, F101, I76 and Y154 
and the positively charged groove residue R73 abrogates DAUDA binding to ZAG by complete or 
partial closure of the groove [19]. Arginine and lysine residues also act as tethers of fatty acids in 
human serum albumin and -lactoglobulin [38, 39]. The ZAG groove contains lysine and tyrosine 
residues which have not been examined so far by site-directed mutagenesis.  
(ii) C16-BODIPY binds to ZAG with a Kd = 0.06 µM, which is slightly stronger than DAUDA (Kd = 
0.11 µM). DAUDA binds to human plasma apolipoprotein D with a similar Kd value of 0.54 µM [40] 
and likewise arachidonic acid with a Kd = 1 µM [41].  These Kd values make it unlikely therefore that 
the C16-BODIPY binding to ZAG is a non-specific surface interaction. This conclusion is reinforced by 
the spectroscopic changes seen by fluorescence (Figures 6A and 6C).  
(iii) Two distinct lipid binding sites were observed in the crystal structure of CD1c, another 
member of the MHC class 1-like immune protein family that present bacterial lipid based antigens to 
T-cells [42]. The crystal structures of five human CD1a-CD1e molecules show two main hydrophobic 
domains (called A’ and F’) (Figure 8C) which vary in size according to the length of the hydrophobic 
chains that they bind [43]. Our results with ZAG show a similar observation with this different 
member of the MHC class 1-like immune protein family, albeit using fluorescently labelled fatty 
acids.  
 
In humans, ZAG expression is reduced in plasma and adipocytes of patients with type 2 diabetes, and 
is associated with insulin resistance [7, 8, 44]. Levels of ZAG are increased in urine from patients with 
type I and type 2 diabetes compared with controls [9, 10]. Similarly, pancreatic zinc is approximately 
50% less in cadavers of diabetic patients compared with non-diabetic cadavers [45] and increased 
urinary zinc levels are observed in diabetes [46, 47]. The total plasma zinc level is about 14.7 µM [48] 
of which the overwhelming majority is bound to human serum albumin as the main zinc buffer in 
plasma [49]. Bioavailable zinc in blood plasma is therefore very low at around 20-210 pM [50], this 
being insufficient to induce ZAG precipitation. In contrast to this, the total zinc concentration of the 
mammalian pancreas is significantly higher than other cell types [51] with zinc concentrations 
reaching 10–20 mM in the interior of the dense-core of beta cell granules [51]. Insulin is stored in 
the pancreatic beta cell granules in crystalline arrays of hexamers containing two zinc ions per 
hexameric unit [52]. Upon secretion from the pancreas into the blood stream the complex 
dissociates forming monomeric insulin. Although ZAG is not expressed in the pancreatic beta-cell 
granules, ZAG has been reported in acinar and peripheral cells of healthy human pancreatic islets [3]. 
It appears likely that ZAG-zinc oligomers are stored in the pancreatic beta cells in a manner similar to 
insulin. Islet amyloid polypeptide or amylin, a neuropancreatic hormone involved in the regulation of 
a range of metabolic parameters forms toxic pancreatic islet amyloid in type 2 diabetes [53]. Amylin 
contains two zinc binding sites; one binds zinc tightly with a Kd value of 1 µM and the other binds 
zinc loosely with a Kd value of about 1 mM. Both zinc binding sites prevent amylin forming amyloid 
fibrils [53]. We previously measured a Kd = 100 µM for the strongest of the weak zinc binding sites in 
ZAG. We speculate therefore that ZAG-zinc oligomers participate in the formation of pancreatic 
amylin plaques in type 2 diabetes by sequestrating high concentrations of zinc. 
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In conclusion, divalent metal binding by ZAG is zinc-specific. Zinc induces the oligomerization of ZAG 
in the absence and presence of fatty acids. The fluorescently-labelled fatty acid C16-BODIPY binds to 
ZAG, while C11-BODIPY does not. The binding of C16-BODIPY to ZAG is reduced in the presence of 
increasing zinc concentrations, but DAUDA binding is almost unaffected. These data support a 
progressive stacking of monomeric ZAG in the presence of Zn2+ whereby the ZAG groove becomes 
partially occluded to suggest the presence of two distinct lipid binding sites in ZAG. Our observation 
may be relevant to storage of ZAG in the pancreas. It will be interesting to discover if toxic 
pancreatic amyloid in type 2 diabetes contains ZAG as well as amylin. 
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Table 1.   Mean hydrodynamic radius (Rh) of ZAG in Hepes buffer. Samples were  titrated with zinc 
chloride or barium chloride followed by excess EDTA. Samples were examined in triplicate and the 
mean Rh value was reported with its standard error (SE).  
 
Table 2.   Dissociation constants Kd for ZAG binding to DAUDA and C16-BODIPY in the presence and 
absence of ZnCl2. The Kd values were generated from a non-competitive single binding site model.  
 Kd (µM) 
[Zinc] (mM) DAUDA C16-BODIPY 
0.0 0.11 ± 0.01 0.06 ± 0.01 
0.5 0.07 ± 0.03 8.70 ± 2.11 
1.0 0.06 ± 0.03 11.11 ± 2.18 
1.5 0.05 ± 0.02 15.38 ± 2.32 
2.0 0.17 ± 0.06 22.80 ± 7.21 
 
  
21  μM ZAG  Rh ± SE (nm) 21  μM ZAG Rh ± SE (nm) 
+ 0.0 mM ZnCl2 3.22 ± 0.18 + 0.0 mM BaCl2 3.22 ± 0.18 
+ 0.5 mM ZnCl2 6.21 ± 0.30 + 0.5mM BaCl2 4.00 ± 0.19 
+ 1.0 mM ZnCl2 7.19 ± 0.34 + 1.0mM BaCl2 4.44 ± 0.41 
+ 1.5 mM ZnCl2 8.05 ± 1.07 + 1.5mM BaCl2 4.63 ± 0.22 
+ 2.0 mM ZnCl2 8.38 ± 1.48 
33.17 ± 9.70 
+ 2.0mM BaCl2 4.23 ± 0.36 
+ 2.0mM ZnCl2 + 
7.5mM EDTA 
4.00 ± 0.19 + 2.0mM BaCl2 + 
7.5mM EDTA 
4.41 ± 0.22 
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FIGURE LEGENDS 
 
Figure 1. Protein purification of ZAG in the presence of divalent metals. (A) size-exclusion 
chromatography of 6.2 µM ZAG (0.2 mg/ml) in the presence of 2 mM of six metal chlorides in Hepes 
buffer at 0.5 ml/min, followed by 7.5 mM EDTA. The ZAG monomer eluted at 23.1 min. The red line 
indicates the size-exclusion chromatography run with 2 mM ZnCl2. (B) Non-reducing gradient 4-20% 
native PAGE of 6.2 µM ZAG in Hepes buffer, with additions of 2 mM metal chlorides (upper panel) 
and increasing concentrations of zinc chloride followed by excess EDTA (lower panel). (C, D) Dynamic 
light scattering of ZAG with additions of zinc and barium chlorides respectively, followed by excess 
EDTA.  
 
Figure 2. Secondary and tertiary structure changes in ZAG with divalent metals. (A) UV absorbance 
spectra of ZAG between 240 nm-400 nm in the absence and presence of 1.8 mM metal chlorides. (B) 
Plot of Turbidity (apparent Absorbance) at 340 nm of ZAG with increasing concentrations of metal 
chloride specified in the panel. (C) Near-UV and (D) Far-UV CD spectra of ZAG in the absence and 
presence of 1.8 mM metal chlorides, with the buffer baseline subtracted from each sample spectrum 
prior to correction for the effects of dilution. All measurements were made using 6.2 µM ZAG in 10 
mM Hepes, pH 7.4, in the absence of NaCl. Data highlighted using a red line indicates the presence 
of ZnCl2. 
 
Figure 3. Sedimentation velocity of ZAG with zinc and barium chlorides. Three sedimentation data 
and boundary fits are shown for (A) 6.2 µM ZAG in Hepes buffer, titrated with (B) 2.0 mM zinc 
chloride and (C) 2.0 mM barium chloride. For clarity, only every third scan is shown in the fitted data 
plots. The sedimentation coefficient c(s) distribution analyses of 6.2 µM ZAG titrated with (D) 
increasing concentrations of zinc chloride, followed by excess EDTA, and (E) increasing 
concentrations of barium chloride followed by excess EDTA. (F) The proportion of ZAG monomer and 
oligomers with increasing concentrations of zinc chloride and barium chloride. The loading 
concentration values were obtained by integration of the c(s) distribution at 50,000 rpm. Data 
highlighted using a red line indicates the presence of 2 mM ZnCl2 or 2mM BaCl2 and green indicates 
the presence of excess EDTA. 
 
Figure 4. Sedimentation velocity of the fluorescent fatty acid C16-BODIPY in the presence of ZAG 
and zinc. The sedimentation boundary fits correspond to (A, B) 6.2 µM ZAG, 6.2 µM C16 BODIPY and 
0.5 mM ZnCl2 and (C, D) 6.2 µM ZAG, 6.2 µM C16 BODIPY and 2.0 mM ZnCl2 in Hepes buffer. For 
clarity only every third scan is shown. Panels (A, C and E) represent the fluorescence-detected 
sedimentation velocity experiments. Panels (B, D and F) represent the absorbance detected 
sedimentation velocity experiments. Data highlighted using a red line indicates the presence of 2 
mM ZnCl2. 
 
Figure 5. X-ray scattering of ZAG with barium chloride. (A) Guinier plot of 15 µM ZAG in the 
presence of increasing barium chloride concentrations in Hepes buffer. (B) Guinier analyses of 15 
µM ZAG in Hepes buffer in the presence of 0.5 mM barium chloride compared with the scattering 
curve calculated from the ZAG crystal structure. (C) Distance distribution P(r) plots of ZAG with 
barium chloride to follow panel (A).   
 
Figure 6. Fluorescence emission spectra of C11-BODIPY and C16-BODIPY with ZAG. Fluorescence 
emission spectra of (A) 0.03 μM C16-BODIPY, (B) 0.04 μM C11-BODIPY in PBS and methanol, (C) 1.11 
µM C16-BODIPY upon addition of 1.11 µM ZAG and (D) 0.04 μM C11-BODIPY upon addition of 20 µM 
ZAG. λex = 488 nm and all fluorescence measurements were corrected for the effects of dilution and 
Raman scattering.  
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Figure 7. Binding of C16-BODIPY and DAUDA to ZAG in the presence of zinc. (A) Fluorescence 
emission spectra at the excitation wavelength λExc = 488 nm of 0.85 μM C16-BODIPY in Hepes buffer 
upon sequential additions of ZAG. (B) Binding curves of C16-BODIPY with ZAG in Hepes buffer 
containing 0 mM, 0.5 mM, 1 mM, 1.5 mM and 2 mM ZnCl2. (C) Fluorescence emission spectra at the 
excitation wavelength λex = 345 nm of 0.89 μM DAUDA in Hepes buffer upon sequential additions of 
ZAG. (D) Binding curves of DAUDA with ZAG in Hepes buffer containing 0 mM, 0.5 mM, 1 mM, 1.5 
mM and 2 mM ZnCl2. All fluorescence data are corrected for the effects of dilution. To account for 
the quenching effect of zinc on C16-BODIPY and DAUDA fluorescences, data points for all binding 
curves were produced by subtraction of the fluorescence emission of each probe from the 
fluorescence emission generated upon additions of ZAG.  
 
Figure 8. Proposed molecular association of ZAG oligomers and its effect on lipid binding in its 
groove. (A) Predicted ZAG monomer, dimer and trimer in the presence of zinc.  (B) Surface diagram 
of the basal and apical surfaces of the ZAG monomer, highlighting potential zinc-binding residues Glu 
(red), His (blue) and Asp (green). The remaining residues are depicted in grey. (C) Three-dimensional 
secondary structure cartoon of the structurally-related immune class I MHC-like molecule Cd1c in 
complex with the pathogenic Mycobacterium tuberculosis lipid antigen mannosyl-β1-
phosphomycoketide (blue spheres) and a C12 alkyl chain (orange spheres) (PDB code 3OV6). All 
images were created using PyMOL software.   
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